A. Neal

The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making

S. Irshad, C. Coles, T. Crook, 2021, BMC cancer.

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study

T. Whelan, I. Kunkler, J. Maduro, 2022, The Lancet.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019, The Lancet.

Predicting axillary lymph node metastases in patients with T1 infiltrating ductal carcinoma of the breast.

S. Ashley, A. Neal, S Ashley, 2001, Breast.